Intravenous oxpentifylline and the painful crisis of sickle cell disease

K. De Ceulaer, G. R. Serjeant, R. L. Nagel, H. H. Billett, J. Christakis, D. Loukopoulos, A. J. Bellingham, G. S. Lucas, J. Stuart

Research output: Contribution to journalArticlepeer-review

7 Scopus citations


Oxpentifylline, a synthetic xanthine derivative with a rheological action on sickle cells in vitro, has been assessed for the treatment of sickle cell painful crisis in a double-blind, placebo-controlled, multi-centre trial of 62 patients. Oxpentifylline was given as a continuous intravenous infusion for a maximum of 96 hours. No statistically significant difference between the placebo and treatment groups was found for the clinical end-points of resolution of local tenderness, restoration of local movement, overall mobility, sleep disturbance, and complete resolution of symptoms.

Original languageEnglish (US)
Pages (from-to)35-42
Number of pages8
JournalClinical Hemorheology
Issue number1
StatePublished - 1990
Externally publishedYes

ASJC Scopus subject areas

  • Physiology
  • Hematology


Dive into the research topics of 'Intravenous oxpentifylline and the painful crisis of sickle cell disease'. Together they form a unique fingerprint.

Cite this